A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Clinical trial NCT03815058 · COMPLETED
Trial details
- NCT number
- NCT03815058
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-21
- Primary completion
- 2025-01-21
- Enrollment
- 131
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.